Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS): 5 pipeline candidates · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.6 months
D/E 29.13 · 3% dilution
Lead: Approved
5 candidates
N/A
0 buys · 14 sells (180d)
A transparent, data-derived signal for Xeris Biopharma Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$115.8M
Quarterly Burn
$61.9M
Runway
7.6 mo
Revenue
$83.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| Gvoke | Approved |
| Keveyis | Approved |
| levothyroxine sodium | Phase 2 |
| Recorlev | Approved |
| XP-8121 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
233
Total value held
$549.9M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 12,945,785 | $75.1M |
| d. e. shaw & co., inc. | 7,788,811 | $45.2M |
| vanguard capital management llc | 6,980,882 | $40.5M |
| state street corp | 4,658,174 | $27.0M |
| geode capital management, llc | 4,290,629 | $24.9M |
| vanguard portfolio management llc | 2,665,608 | $15.5M |
| morgan stanley | 2,572,654 | $14.9M |
| millennium management llc | 2,265,974 | $13.1M |
| wellington management group llp | 2,171,354 | $12.6M |
| two sigma investments, lp | 1,924,202 | $11.2M |
Showing top 10 of 233 institutional holders of Xeris Biopharma Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Xeris Biopharma Holdings, Inc.'s pipeline?
Xeris Biopharma Holdings, Inc. (XERS) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Xeris Biopharma Holdings, Inc.'s lead drug candidate?
Xeris Biopharma Holdings, Inc.'s most advanced tracked candidate is Gvoke (Approved) for Treatment of severe hypoglycemia; indicated for use in pediatric and adult patients with diabetes age two years and above.
What is Xeris Biopharma Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Xeris Biopharma Holdings, Inc. has approximately 7.6 months of cash runway.
What is Xeris Biopharma Holdings, Inc.'s market capitalization?
Xeris Biopharma Holdings, Inc.'s market capitalization is approximately $1.2B.
Who is the CEO of Xeris Biopharma Holdings, Inc.?
Mr. John P. Shannon is the chief executive officer of Xeris Biopharma Holdings, Inc. (XERS).
Get the full picture on Xeris Biopharma Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.